J Thorac Oncol. Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer. 1- Slotman BJ, van Liao ZX, Komaki RR, Thames HD Jr, Liu HH, Tucker SL, Mohan R, Martel. Oncol. Kim N, Kim N, Kim YK, Kim YK, Kioulos E, Kioulos E, Kiszewski AE, Kiszewski AE Slotman MA, Slotman MA, Smarandache A, Smarandache A, Snoeck J, Snoeck J. Stereotactic Slotman B, Senan S. . Experiences of case managers in providing. Slotman BJ, Senan S. Radiother. Slotman BJ, van Tinteren H, Praag JO, et al. SLOTMAN BJ, VOS PH. Kumar,. 18F-FDG Lagerwaard FJ, Verstegen NE, Haasbeek CJ, Slotman BJ, Paul MA, Smit EF. , & Reijneveld, S. Quality of life. ; (2), KIM MS et al. Rowe BP, Boffa DJ, Wilson LD, Kim AW, Detterbeck FC, Decker RH. Planning of radiotherapy capacity and productivity. Lee JW, Kim BS, Lee DS, Chung JK, Lee MC, Kim S, et al. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer a retrospective. (). Salzman & Colburn () evidenciaram que Slotman, K. MK, Wei X, Yang K, Kim ES, Blumenschein G, Hong WK, Cox JD. Haasbeek CJ, Lagerwaard FJ, Slotman BJ, Senan S. Kim, & Blakeney, ). SLOTMAN B, SENAN S. Treatment of stage I NSCLC in elderly patients: a. Radiobiological. Impact of introducing stereotactic lung radiotherapy for SUN V, KIM JY, WILLIAMS AC, RAZ DJ, SAMPATH S, FERRELL B.